iNKT cell-based immunotherapy (University of California)

N/A

Report date: 2025/03/20 15:02:35

Base Information

Drug NameiNKT cell-based immunotherapy (University of California)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionImmunomodulatorsNatural killer cells modulators
TargetsUpdating
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Immune System DiseasesNeoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of California
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Immune System DiseasesNeoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A